Banner - NPPA Connect
Opinion|Videos|December 5, 2024

Balancing Safety and Efficacy With Key Data

Key Takeaways

James Song, MD, discusses how clinical trial data demonstrates the risk-benefit profile of vitiligo therapies, with particular focus on balancing potential adverse effects of Janus kinase inhibitors against their proven efficacy in achieving repigmentation.


Latest CME